PharmaCyte Biotech, Inc. (PMCB) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.7x

Market Cap

$5.22M

MomentumView details →

1D Return

−0.98%

YTD Return

−32.47%

RSI (14)

31.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.7x

Market Cap

$5.22M

RSI (14)

31.6

MomentumView details →

1D Return

−0.98%

YTD Return

−32.47%

SummaryUpdated Apr 1, 2026

PharmaCyte Biotech, Inc. (OTCQB:PMCB) is a biotechnology company founded in 1996 and headquartered in Las Vegas, Nevada. Originally incorporated as Nuvilex, Inc., the company changed its name to PharmaCyte Biotech in January 2015 and went public in 2013. The company is a clinical-stage biotechnology firm focused on developing innovative cellular therapies for treating cancer, diabetes, and malignant ascites using its proprietary encapsulation technology platform.

Ask drillr about PharmaCyte Biotech, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−58.34%

ROA (TTM)

−41.55%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−70.67%

EarningsView details →

EPS (Actual)

−$0.01

EPS Surprise

83.33%

Beats (12Q)

2/12

Next Q EPS Est

−$0.06

Avg Surprise (4Q)

40.28%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

45.28x

Quick Ratio

45.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−19.42M

Op. CF (TTM)

−5.15M

Latest newsMore news →

No recent news for PMCB.

Similar companies

HCW Biologics Inc.HCWB Klotho Neurosciences, Inc.KLTOW Niki BioSolutions, Inc.NIKI Liminatus Pharma, Inc. Class A Common StockLIMN Pulmatrix, Inc.PULM Cardio Diagnostics Holdings, Inc.CDIO Find similar companies →

Latest newsMore news →

No recent news for PMCB.